Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non–small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial

Víctor Moreno; Desamparados Roda; Joanna Pikiel; José Trigo; Joaquim Bosch‐Barrera; Yvette Drew; Rebecca Kristeleit; Sandrine Hiret; David L. Bajor; Patricia Cruz; J. Thaddeus Beck; Srimoyee Ghosh; Christine Dabrowski; Grace Antony; Tao Duan; Jennifer Veneris; Eleftherios Zografos; Janakiraman Subramanian

doi:10.1016/j.cllc.2022.05.013

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Dostarlimab demonstrated promising antitumor activity in advanced/recurrent NSCLC that progressed following platinum-based chemotherapy, including across all PD-L1 subgroups, and has an acceptable safety profile.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Moreno et al. (2022) studied this question.

synapsesocial.com/papers/69d98abf8988aeabbe685a48 https://doi.org/10.1016/j.cllc.2022.05.013

View Full Paper

Ask AI

Bookmark

Share

Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non–small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non–small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading